BACKGROUND & AIMS: Chronic granulomatous disease (CGD) is a rare genetic disorder, predisposing affected individuals to recurrent infectious complications and shortened survival. Liver involvement in CGD includes vascular abnormalities, which may lead to noncirrhotic portal hypertension. METHODS: To evaluate the impact of noncirrhotic portal hypertension on survival in CGD, all records from 194 patients followed up at the National Institutes of Health with CGD were reviewed. Cox proportional hazards regression was used to determine factors associated with mortality. RESULTS: Twenty-four patients died, all from infectious complications. By Cox regression, factors associated with mortality were as follows: (1) decreases in platelet count (>9000/microL/y; hazard ratio, 4.7; P = .007), (2) alkaline phosphatase level increases (>0.25/y; hazard ratio, 4.5; P = .01) and (3) history of liver abscess (hazard ratio, 3.1; P = .03). By regression analysis, decreasing platelet count was associated with increasing portal vein diameter, splenomegaly, increased serum immunoglobulin G level, and increasing number of alanine aminotransferase increases; greater number of alkaline phosphatase level increases and abscess were both associated with increasing age and number of infections. Prospective evaluation revealed increased hepatic-venous pressure gradients in 2 patients with progressive thrombocytopenia, suggestive of portal hypertension. CONCLUSIONS: These data suggest mortality in patients with CGD is associated with the development of noncirrhotic portal hypertension, likely owing to injury to the microvasculature of the liver from repeated systemic and hepatic infections. The slope of decline in platelet count may be a useful measure of progression of portal hypertension over time. Furthermore, the data illustrate the potential independent effect of portal hypertension on clinical outcome outside the setting of cirrhosis.
BACKGROUND & AIMS:Chronic granulomatous disease (CGD) is a rare genetic disorder, predisposing affected individuals to recurrent infectious complications and shortened survival. Liver involvement in CGD includes vascular abnormalities, which may lead to noncirrhotic portal hypertension. METHODS: To evaluate the impact of noncirrhotic portal hypertension on survival in CGD, all records from 194 patients followed up at the National Institutes of Health with CGD were reviewed. Cox proportional hazards regression was used to determine factors associated with mortality. RESULTS: Twenty-four patients died, all from infectious complications. By Cox regression, factors associated with mortality were as follows: (1) decreases in platelet count (>9000/microL/y; hazard ratio, 4.7; P = .007), (2) alkaline phosphatase level increases (>0.25/y; hazard ratio, 4.5; P = .01) and (3) history of liver abscess (hazard ratio, 3.1; P = .03). By regression analysis, decreasing platelet count was associated with increasing portal vein diameter, splenomegaly, increased serum immunoglobulin G level, and increasing number of alanine aminotransferase increases; greater number of alkaline phosphatase level increases and abscess were both associated with increasing age and number of infections. Prospective evaluation revealed increased hepatic-venous pressure gradients in 2 patients with progressive thrombocytopenia, suggestive of portal hypertension. CONCLUSIONS: These data suggest mortality in patients with CGD is associated with the development of noncirrhotic portal hypertension, likely owing to injury to the microvasculature of the liver from repeated systemic and hepatic infections. The slope of decline in platelet count may be a useful measure of progression of portal hypertension over time. Furthermore, the data illustrate the potential independent effect of portal hypertension on clinical outcome outside the setting of cirrhosis.
Authors: F Schepis; C Cammà; D Niceforo; A Magnano; S Pallio; M Cinquegrani; G D'amico; L Pasta; A Craxì; A Saitta; G Raimondo Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Brindhesha Rasaratnam; David Kaye; Garry Jennings; Francis Dudley; Jaye Chin-Dusting Journal: Ann Intern Med Date: 2003-08-05 Impact factor: 25.391
Authors: Marla C Dubinsky; Eric A Vasiliauskas; Hardeep Singh; Maria T Abreu; Kostas A Papadakis; Tram Tran; Paul Martin; John M Vierling; Stephen A Geller; Stephan R Targan; Fred F Poordad Journal: Gastroenterology Date: 2003-08 Impact factor: 22.682
Authors: John I Gallin; David W Alling; Harry L Malech; Robert Wesley; Deloris Koziol; Beatriz Marciano; Eli M Eisenstein; Maria L Turner; Ellen S DeCarlo; Judith M Starling; Steven M Holland Journal: N Engl J Med Date: 2003-06-12 Impact factor: 91.245
Authors: Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech Journal: J Allergy Clin Immunol Date: 2011-04-17 Impact factor: 10.793
Authors: Christopher Koh; Sasan Sakiani; Pallavi Surana; Xiongce Zhao; Jason Eccleston; David E Kleiner; David Herion; T Jake Liang; Jay H Hoofnagle; Milica Chernick; Theo Heller Journal: Hepatology Date: 2017-06-26 Impact factor: 17.425
Authors: David M Straughan; Kaitlin C McLoughlin; John E Mullinax; Beatriz E Marciano; Alexandra F Freeman; Victoria L Anderson; Gulbu Uzel; Said C Azoury; Rebecca Sorber; Humair S Quadri; Harry L Malech; Suk See DeRavin; Natasha Kamal; Christopher Koh; Christa S Zerbe; Douglas B Kuhns; John I Gallin; Theo Heller; Steven M Holland; Udo Rudloff Journal: Clin Infect Dis Date: 2018-04-17 Impact factor: 9.079
Authors: Joy X Jiang; Senthil Venugopal; Nobuko Serizawa; Xiangling Chen; Fiona Scott; Yong Li; Roger Adamson; Sridevi Devaraj; Vijay Shah; M Eric Gershwin; Scott L Friedman; Natalie J Török Journal: Gastroenterology Date: 2010-06-01 Impact factor: 22.682